Form 4: Pfizer Director Acquires Phantom Stock Units

Pfizer Director James Quincey acquired 1,433.062 phantom stock units as deferred compensation, increasing his total beneficial ownership.

Summary

• James Quincey, a Director of Pfizer Inc. (PFE), acquired 1,433.062 phantom stock units on March 27, 2026.
• The acquisition price for these units was $27.04 per unit.
• These units represent deferred director's compensation, including dividend equivalents, and will be settled in cash or common stock at the director's election following retirement from the Board.
• Following this transaction, James Quincey beneficially owns a total of 77,317.538 phantom stock units.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a routine, slightly positive event, as it indicates a director's continued accumulation of company-linked compensation, aligning their interests with long-term shareholder value.

Positives

• Director James Quincey increased his beneficial ownership in Pfizer through the acquisition of 1,433.062 phantom stock units.
• The acquisition is part of a deferred director's compensation plan, which aligns director interests with long-term shareholder value.

Risks

• The value of the phantom stock units is tied to the future performance of Pfizer's common stock, introducing market risk until settlement.

Future Outlook

The filing indicates a long-term compensation structure for a director, suggesting continued alignment of management interests with future company performance, as these units settle upon retirement.

Industry Context

StockSavvy.ai notes that deferred compensation in the form of phantom stock units is a common practice in the pharmaceutical industry to retain key directors and align their long-term interests with shareholder value, particularly for large, established companies like Pfizer.

Comparison to Industry Standards

• Deferred compensation plans, including phantom stock units, are standard practice for director remuneration in large-cap pharmaceutical companies such as Johnson & Johnson (JNJ) and Merck & Co. (MRK), aiming to foster long-term commitment.
• The structure, where units convert to cash or common stock upon retirement, is consistent with governance best practices seen across global benchmarks for executive and director compensation.

Corporate Governance

Related Party Transactions

• The acquisition of phantom stock units by Director James Quincey represents a related party transaction as part of his deferred compensation.

Stakeholder Impact

• Shareholders: The transaction aligns the director's financial interests with the long-term performance of the company's stock, potentially benefiting shareholders through improved governance and strategic decisions.

Next Steps

• The phantom stock units will be settled in cash or common stock at the director's election following retirement from the Board of Directors.

Key Dates

Recommendation

This Form 4 reports a routine insider transaction related to deferred director compensation. While it shows continued director alignment, it does not present new information significant enough to alter an investment thesis or warrant a change in recommendation for Pfizer stock.

Keywords

Pfizer, PFE, Form 4, Insider Transaction, Phantom Stock Units, Director Compensation, James Quincey, Beneficial Ownership